The combined inhibition of IDO1, CTLA4, and CD274 (an immunosuppressive molecule best known as PD-L1) has been shown to mediate superior therapeutic effects against well-established gliomas in mice and induce the antitumor immune responses (69, 70). Here, CD274 is linked to central nervous system cancer.